Kailera Therapeutics, Inc.

NASDAQ:KLRA

Biotechnology

Healthcare
$11.79 +2.66%

+$0.51 today

Market cap
$1.53B
Beta
0.00
52W Low $18.50High $28.23

Volume 0.42M

Average 0.80M

KLRA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Kailera Therapeutics, Inc.NASDAQ: KLRA

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA of -$111.31M in Q2 FY2026

Q2 FY2026 EBITDA was -$111.31M.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$111.31M-31.6% QoQ
Last fiscal yearDec 2025
-$158.03M— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+100.0%—
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(158.03M) USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How KLRA compares with its peers on the latest reported figures

  • KLRA's FY2025 EBITDA of -$158.03M is the 8th highest of the 10 companies compared; the peer median is -$89.21M.
KLRA Competitors Peer median
EBITDA for KLRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$78.84M +1391.3%——
VTVTvTv Therapeutics Inc.LTM Mar 2026-$715K +96.9%—1.9%
BMEABiomea Fusion, Inc.LTM Mar 2026-$46.12M +63.6%——
ALTAltimmune, Inc.LTM Mar 2026-$88.27M +2.7%—245200.0%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.21M -28.4%—864.8%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$106.88M -21.2%——
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$148.59M -85.2%——
KLRAKailera Therapeutics, Inc.FY2025-$158.03M ———
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026-$254.91M -32.5%—3579.7%
VKTXViking Therapeutics, Inc.LTM Jun 2026-$534.34M -212.4%——
Peer median (excluding KLRA) -$89.21M-21.2%—2222.2%

Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kailera Therapeutics, Inc.

NASDAQ:KLRA

Intrinsic Alpha fair value

Locked

Current Price

$11.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.